Drawing on the research generated from decades of our work, we created AltPep to improve human health through the early detection and treatment of amyloid diseases.

Drawing upon decades of research in the Daggett Research Group at the University of Washington, AltPep approaches the progression of amyloid diseases in a novel way. By developing and employing innovative computer modeling techniques, they discovered a new protein structure (alpha-sheet) linked to toxic misfolded aggregates — the underlying cause of 50 human amyloid diseases, including Alzheimer’s Disease and biofilm-associated multidrug-resistant infections. AltPep's unique and proprietary platform specifically targets only the toxic alpha-sheets that lead to disease, paving the way for diagnostic tools to detect disease decades earlier than current technologies, and disease-modifying therapeutics to hinder the disease's development. This stands in contrast to current approaches that address symptoms as they appear, which come after 10-20 years of damage wrought by the toxic aggregates.